All articles tagged with #liraglutide
Scientists developed a new imaging method revealing that immune cells in the eye become hyperactive early in diabetic retinopathy, before visible damage occurs. The drug liraglutide normalizes this activity, offering potential for early diagnosis and treatment to prevent blindness.
A small Italian study suggests that GLP-1 drugs like liraglutide, used for weight loss, may also significantly reduce the frequency and severity of chronic migraines, independent of weight loss, indicating a potential new off-label use for these medications. Further research is needed to confirm these findings.
A pilot study suggests that GLP-1 agonists like liraglutide, originally used for diabetes and weight loss, may significantly reduce the frequency of chronic migraines, potentially through mechanisms independent of weight loss, such as lowering intracranial pressure. Further research is needed to confirm these findings.
A pilot study suggests that GLP-1 receptor agonists like liraglutide, similar to Ozempic, may significantly reduce the frequency of chronic migraines, with some patients experiencing up to a 75% reduction, potentially through lowering intracranial pressure, though further research is needed.
Early research suggests that the GLP-1 agonist liraglutide, used for diabetes and obesity, may significantly reduce migraine days, potentially through mechanisms involving brain pressure and CGRP reduction, but larger, controlled studies are needed to confirm these findings.
A small study suggests that GLP-1 drugs like liraglutide, used for diabetes and weight loss, may significantly reduce migraine days by lowering brain pressure, with promising results for future larger trials.
A study from the University of Copenhagen suggests that combining liraglutide injections with a supervised exercise program helps patients maintain weight loss better after stopping the drugs. The study compared body weight changes after exercise, pharmaceutical interventions, or both treatments combined. It found that while liraglutide can result in weight loss comparable to exercise on its own, exercise is more effective at maintaining weight loss in the long run. Participants who combined liraglutide with supervised exercise were able to sustain a weight loss of at least 10 percent of their initial weight a year after stopping treatment, showing better outcomes than those in the exercise-only group. The study highlights the importance of exercise in maintaining weight loss and suggests that more research is needed to explore how weight-loss drugs like liraglutide can be used most effectively for long-term weight maintenance.
A small study presented at the American Association for the Advancement of Science conference found that the anti-obesity drug liraglutide significantly reduced opioid cravings in patients with opioid use disorder. The study, funded by the National Institute of Drug Abuse and pharma company Novo Nordisk, showed a 30% reduction in cravings over a three-week period, with potential for an additive effect when combined with buprenorphine. While the drug was found to be safe, gastrointestinal distress led to a high drop-out rate, suggesting the need for further investigation. Despite limitations, the findings suggest liraglutide could be a promising adjunct to existing treatments for opioid addiction.
A new study has found that GLP-1 drugs, such as liraglutide, can help people who have undergone bariatric surgery but did not achieve their weight loss goals. These drugs suppress appetite and improve glucose, cholesterol, and blood pressure levels, contributing to weight loss. The study showed that taking liraglutide led to significant reductions in body fat and weight, as well as positive changes in other health markers. GLP-1 drugs act on the same mechanisms as bariatric surgery and can be used to optimize surgery outcomes.
Advisers to the World Health Organization will consider adding liraglutide, the active ingredient in certain diabetes and obesity medications, to its list of essential medicines. The drug mimics the effects of an appetite-regulating hormone and stimulates the release of insulin, helping to lower blood sugar and slow the passage of food through the gut. The request to add GLP-1 receptor agonists such as liraglutide came from four researchers at US institutions. WHO’s advisers will make recommendations on which drugs should be included in this year’s list, expected to come in September.